hrcak mascot   Srce   HID

Izvorni znanstveni članak

ML20474 STUDY: CROATIAN EXPERIENCE IN EFFICACY AND SAFETY OF ANEMIA CORRECTION IN PREDIALYSIS PATIENTS

INGRID PRKAčIN   ORCID icon orcid.org/0000-0002-5830-7131 ; Merkur Clinical Hospital, Zagreb University School of Medicine, Department of Internal medicine, Zagreb, Croatia
DRAGAN KLARIć ; Zadar General Hospital, Department of Nephrology and Dialysis, Zadar, Croatia
VESNA LOVčIć ; Bjelovar General Hospital, Department of Internal medicine, Bjelovar, Croatia
KREšIMIR GALEšIć ; Dubrava University Hospital, Department of Nephrology, Zagreb, Croatia
MARIO ILIć ; Dubrovnik General Hospital, Department of Internal medicine, Dubrovnik, Croatia
SANJIN RAčKI ; Rijeka University Hospital Center, Department of Nephrology and Dialysis, Rijeka, Croatia

Puni tekst: hrvatski, pdf (219 KB) str. 18-18 preuzimanja: 97* citiraj
APA 6th Edition
PRKAčIN, I., KLARIć, D., LOVčIć, V., GALEšIć, K., ILIć, M. i RAčKI, S. (2016). STuDIJA ML20474 PRIMJENE ERITROPOETINA BETA (NEORECORMON) u LIJEčENJu ANEMIJE PREDIJALIZNIH BOLESNIKA – HRVATSKO ISKuSTVO. Acta medica Croatica, 70 (Suplement 2), 18-18. Preuzeto s https://hrcak.srce.hr/180117
MLA 8th Edition
PRKAčIN, INGRID, et al. "STuDIJA ML20474 PRIMJENE ERITROPOETINA BETA (NEORECORMON) u LIJEčENJu ANEMIJE PREDIJALIZNIH BOLESNIKA – HRVATSKO ISKuSTVO." Acta medica Croatica, vol. 70, br. Suplement 2, 2016, str. 18-18. https://hrcak.srce.hr/180117. Citirano 22.10.2019.
Chicago 17th Edition
PRKAčIN, INGRID, DRAGAN KLARIć, VESNA LOVčIć, KREšIMIR GALEšIć, MARIO ILIć i SANJIN RAčKI. "STuDIJA ML20474 PRIMJENE ERITROPOETINA BETA (NEORECORMON) u LIJEčENJu ANEMIJE PREDIJALIZNIH BOLESNIKA – HRVATSKO ISKuSTVO." Acta medica Croatica 70, br. Suplement 2 (2016): 18-18. https://hrcak.srce.hr/180117
Harvard
PRKAčIN, I., et al. (2016). 'STuDIJA ML20474 PRIMJENE ERITROPOETINA BETA (NEORECORMON) u LIJEčENJu ANEMIJE PREDIJALIZNIH BOLESNIKA – HRVATSKO ISKuSTVO', Acta medica Croatica, 70(Suplement 2), str. 18-18. Preuzeto s: https://hrcak.srce.hr/180117 (Datum pristupa: 22.10.2019.)
Vancouver
PRKAčIN I, KLARIć D, LOVčIć V, GALEšIć K, ILIć M, RAčKI S. STuDIJA ML20474 PRIMJENE ERITROPOETINA BETA (NEORECORMON) u LIJEčENJu ANEMIJE PREDIJALIZNIH BOLESNIKA – HRVATSKO ISKuSTVO. Acta medica Croatica [Internet]. 2016 [pristupljeno 22.10.2019.];70(Suplement 2):18-18. Dostupno na: https://hrcak.srce.hr/180117
IEEE
I. PRKAčIN, D. KLARIć, V. LOVčIć, K. GALEšIć, M. ILIć i S. RAčKI, "STuDIJA ML20474 PRIMJENE ERITROPOETINA BETA (NEORECORMON) u LIJEčENJu ANEMIJE PREDIJALIZNIH BOLESNIKA – HRVATSKO ISKuSTVO", Acta medica Croatica, vol.70, br. Suplement 2, str. 18-18, 2016. [Online]. Dostupno na: https://hrcak.srce.hr/180117. [Citirano: 22.10.2019.]

Sažetak
We performed observational multicenter study on CKD patients in stage 3-5, with renal anemia. Key inclusion criteria were: haemoglobin level > 6.0 g/dL, age >18 years and written inform consent. Exclusion criteria were dialysis and transplanted patients and haemoglobin level > 12.0 g/dL. Study was performed from 2006.-2012. and 368 patients were included. All patients received Erythropoietin beta (Neorecormon®; Roche, Basel, Switzerland) subcutaneously in dose of 4000-6000 IU every week during the correction phase of anemia treatment or once weekly 2000-4000IU during the maintenance treatment. Iron supplementation was administrated orally in >80% patients in order to achieve serum ferritin 200-500 μg/L. From 368 patients on beginning, 246 were followed and statistically analyzed (M:F=136/110). Mean duration study period was 13.6 (Std.dev.10.36) months (max 52 months). Patients were mainly men (55.3%), age >51 years (81.3%). The median of Hb level at baseline was 9.35 g/dL and after 12 months 10.4 g/dL respectively. After 12 months, most of patients had Hb range 10.0 g/dL to 11.0 g/dL. There were no statistically significant differences between Hb in groups of patients stratified according to the primary kidney disease and age, and between sex: mean level of Hb in M at the end of study was 10.27 g/dl and in F 10.58 g/dl (p=0.051). Baseline eGFR (Cocroft Gault) values were 16.31 (range form 4.1-62.6) vs. 16.71 (range from 4.9-43.8) mL/min after 12 months. The majority of patients had reported better exercise tolerance and sleep. 47.7% of patients have started after predialysis education with dialysis and in 2 patients preemptive transplantation was performed. The results of this multicenter observational study in Croatia suggest that the use of erythropoietin beta is effective and safe in correction of anemia in pre-dialysis CKD patients.

Ključne riječi
anemia; non-dialysis chronic kidney disease

Hrčak ID: 180117

URI
https://hrcak.srce.hr/180117

[hrvatski]

Posjeta: 212 *